Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 58 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Mr. Brendan O'Grady est le Chief Executive Officer de Assertio Holdings Inc, il a rejoint l'entreprise depuis 2024.
Quelle est la performance du prix de l'action ASRT ?
Le prix actuel de ASRT est de $14.9, il a diminué de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Assertio Holdings Inc ?
Assertio Holdings Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quel est la capitalisation boursière de Assertio Holdings Inc ?
La capitalisation boursière actuelle de Assertio Holdings Inc est de $95.6M
Est-ce que Assertio Holdings Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 6 analystes ont établi des notations d'analystes pour Assertio Holdings Inc, y compris 2 achat fort, 7 achat, 1 maintien, 0 vente et 2 vente forte